Compare · ILMN vs SPNE
ILMN vs SPNE
Side-by-side comparison of Illumina Inc. (ILMN) and SeaSpine Holdings Corporation (SPNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and SPNE operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $25.86B, about 62.3x SPNE ($415.1M).
- ILMN has hit the wire 24 times in the past 4 weeks while SPNE has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 5 for SPNE).
- Company
- Illumina Inc.
- SeaSpine Holdings Corporation
- Price
- $171.04+5.25%
- $9.52+8.18%
- Market cap
- $25.86B
- $415.1M
- 1M return
- +22.71%
- -
- 1Y return
- +109.10%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 24
- 0
- Recent ratings
- 25
- 5
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
SeaSpine Holdings Corporation
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and demineralized bone matrices. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in degenerative, minimally invasive surgery, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical spine. The company has development and licensing agreement with restor3d, Inc. and 7D Surgical, Inc. to develop 3D-printed interbody devices. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.
Latest ILMN
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director King David P was granted 2,072 shares (SEC Form 4)
- Director Siegel Susan E was granted 2,072 shares, increasing direct ownership by 14% to 16,535 units (SEC Form 4)
Latest SPNE
- SEC Form CT ORDER filed by SeaSpine Holdings Corporation
- SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)
- SEC Form 15-12G filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form 4: Stephenson Kirtley C. returned 138,340 shares to the company, closing all direct ownership in the company
- SEC Form 4: Steinway Angela returned 23,725 shares to the company, closing all direct ownership in the company
- SEC Form 4: Maniar Shweta returned 23,993 shares to the company, closing all direct ownership in the company
- SEC Form 4: Gaeta Renee returned 36,056 shares to the company, closing all direct ownership in the company